IIG Seminar - The tumor antigenic landscape associated with T cell infiltration and immunoediting.

The Bassani-Sternberg lab focuses on identifying clinically relevant cancer-specific Human Leukocyte Antigen (HLA) ligands that will guide the development of personalized cancer immunotherapy using mass-spectrometry (MS), currently the only methodology to identify unbiasedly HLA binding peptides that are presented in vivo to cytotoxic T cells. Her group has developed proteogenomics and MS-based immunopeptidomics analytical and computational approaches to identify HLA ligands derived from tumor-associated proteins, mutated neoantigens, non-canonical ORFs and post translationally modified peptides. In the clinic, the Bassani-Sternberg group aims to integrate, for the first time, mass-spectrometry-based immunopeptidomics into the innovative translational clinical strategy of personalized immunotherapy within the department of oncology. Dr. Bassani-Sternberg aims to apply her group ’ s discovery pipeline in the context of phase I clinical vaccine and adoptive T cell therapy trials to identify personalized neoantigens from patient tumor samples.For more information go tohttps://www.niaid.nih.gov/research/immunology-seminarsAir date: 4/5/2023 4:00:00 PM
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video